Drug intelligence / Profile preview

SCB-2019 + AS03

Development stage: Unknown
Lead developer: Clover Biopharmaceuticals
Modality: Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SCB-2019 + AS03 is a protein subunit COVID-19 vaccine candidate that combines SCB-2019 (S-Trimer), a stabilized trimeric form of the SARS-CoV-2 spike protein, with the AS03 adjuvant from GSK. In Phase I clinical trials, this formulation elicited robust humoral and cellular immune responses against SARS-CoV-2, with high viral neutralizing activity. The vaccine demonstrated strong antibody responses with geometric mean titers of 1567-4452 and was generally well-tolerated, though it had a higher frequency of local adverse events (primarily mild injection site pain) compared to other formulations.

Other names: S-Trimer + AS03

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on SCB-2019 + AS03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCB-2019 + AS03.

Explore the full profile